Polyphenol Metabotypes in People with Diabetes Type 2

NCT ID: NCT06810635

Last Updated: 2025-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus (T2DM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T2DM

persons with type 2 diabetes mellitus

Oral Polyphenol Challenge Test / PPPIL

Intervention Type DIETARY_SUPPLEMENT

Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)

fasting blood sample

Intervention Type DIAGNOSTIC_TEST

Fasting blood sample will be obtained for determination of markers of metabolic health.

Fasting urine collection

Intervention Type DIAGNOSTIC_TEST

Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites

24 hours urine collection

Intervention Type DIAGNOSTIC_TEST

Subjects collect urine over the entire 24h. for determination of polyphenol metabolites

Questionnaires

Intervention Type OTHER

Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.

Stool collection

Intervention Type DIAGNOSTIC_TEST

Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.

Transit time determination

Intervention Type DIAGNOSTIC_TEST

Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.

Non diabetic persons

This cohort is a group without type 2 diabetes or any other chronic illness

Oral Polyphenol Challenge Test / PPPIL

Intervention Type DIETARY_SUPPLEMENT

Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)

fasting blood sample

Intervention Type DIAGNOSTIC_TEST

Fasting blood sample will be obtained for determination of markers of metabolic health.

Fasting urine collection

Intervention Type DIAGNOSTIC_TEST

Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites

24 hours urine collection

Intervention Type DIAGNOSTIC_TEST

Subjects collect urine over the entire 24h. for determination of polyphenol metabolites

Questionnaires

Intervention Type OTHER

Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.

Stool collection

Intervention Type DIAGNOSTIC_TEST

Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.

Transit time determination

Intervention Type DIAGNOSTIC_TEST

Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Polyphenol Challenge Test / PPPIL

Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)

Intervention Type DIETARY_SUPPLEMENT

fasting blood sample

Fasting blood sample will be obtained for determination of markers of metabolic health.

Intervention Type DIAGNOSTIC_TEST

Fasting urine collection

Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites

Intervention Type DIAGNOSTIC_TEST

24 hours urine collection

Subjects collect urine over the entire 24h. for determination of polyphenol metabolites

Intervention Type DIAGNOSTIC_TEST

Questionnaires

Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.

Intervention Type OTHER

Stool collection

Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.

Intervention Type DIAGNOSTIC_TEST

Transit time determination

Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all participants
* between 40-85 years
* age-matched individuals without diabetes
* BMI between 18.5-30
* no metabolic syndrome
* persons with T2DM
* at leats 2 years of clinical diagnoses of T2DM
* stable medication use for at least 1 month

Exclusion Criteria

* pregnancy of breastfeeding
* in last month
* acute use of anti/pre/probiotics
* start of new drug or dietary supplements
* major changes in diet
* major lifestyle changes
* diseases
* Gastrointestinal diseases (inflammatory bowel disease)
* Bariatric surgery
* Other forms of diabetes (cystic fibrosis/MODY/T1DM)
* Heart problems (NYHA 3/4) or previous cardiovascular events
* Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis
* Lung problems (COPD - GOLD 3/4), cystic fibrosis
* Uncontrolled thyroid function disruption in the past 6 months
* Intake of coumarin derivatives and direct oral anticoagulant medication
* Anti-cancer treatment: chemo-/immunotherapy
* Immonosuppressants (transplant)
* Antiepileptic drugs
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Ghent

OTHER

Sponsor Role collaborator

University of Parma

OTHER

Sponsor Role collaborator

Universiteit Antwerpen

OTHER

Sponsor Role collaborator

University Hospital, Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno Lapauw, Professor

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Ghent

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ghent University

Ghent, East Flanders, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jan Stautemas, PhD

Role: CONTACT

003293328967

Patrick Calders, Professor

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jan Stautemas

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ONZ-2023-0601

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Antioxidant Treatment of Type 2 Diabetes
NCT00609102 COMPLETED EARLY_PHASE1